Newbury Pharmaceuticals AB is a Sweden-based pharmaceutical company for specialty prescription drugs. The Companyâ€™s existing portfolio is focused on the Scandinavian market and consists of pharmaceuticals from several therapeutic areas with oncology, rare diseases and neurology.

Employees

Sector

Drug Retailers

Calendar

12-16 Earnings release - Annual 2025

More about the company

Quotes

Date	Price	Change	Volume
26-10-29	SEK 1.580	+1.28%	41,554
26-10-28	SEK 1.560	-6.31%	145,475
26-10-27	SEK 1.665	+4.06%	121,902
26-10-26	SEK 1.600	-3.32%	85,765
26-10-23	SEK 1.655	-3.78%	78,506

Delayed Quote Nasdaq Stockholm

More quotes

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - Newbury Pharmaceuticals AB

Company calendar

Market Closed - Nasdaq Stockholm 13:00:00 2026-10-29 EDT			5-day change	1st Jan Change
1.580 ^SEK	+1.28%		-8.14%	+37.39%

10-28	Newbury Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended August 31, 2026	CI
10-27	Newbury's Generic Version of Resolor Gets Marketing Authorization in Sweden	MT

Market Cap	76.3M 7.74M 6.93M 6.4M 5.79M 10.82M 737M 11M 30.44M 386M 29.04M 28.43M 1.22B	P/E 2024	-4.59x	P/E 2025	-2.81x
Enterprise Value	61.74M 6.26M 5.61M 5.17M 4.68M 8.76M 596M 8.9M 24.63M 312M 23.5M 23M 988M	EV / Sales 2024	1.76x	EV / Sales 2025	2.03x
Free-Float	25.89%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq Stockholm	NEWBRY	Delayed
Deutsche Boerse AG	P52	Delayed

10-28	Newbury Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended August 31, 2026	CI
10-27	Newbury's Generic Version of Resolor Gets Marketing Authorization in Sweden	MT
09-28	Newbury Pharmaceuticals AB, through its subsidiary Newbury Pharmaceuticals S.A Secure Exclusive Rights to 40-Product Hospital Portfolio in Iraq	CI
07-13	Newbury Pharmaceuticals Secures Generic Approval for Tofacitinib Newbury	CI
07-10	Newbury Pharmaceuticals Secures Generic Approval for Dalbavancin Newbury	CI
07-08	Newbury Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026	CI
06-16	Navamedic CEO Steps Down; Successor Named	MT
04-17	Newbury Pharmaceuticals Wins Danish Approval for Generic Breast Cancer Drug	MT
04-17	Newbury Pharmaceuticals Secures Generic Approval for Palbociclib Newbury	CI
04-15	Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2026	CI
04-15	Newbury pharmaceuticals Q2 EBITDA loss deepens to SEK 4.1 million	RE
04-15	Newbury Pharmaceuticals AB Provides Earnings Guidance for the Second Half of the Financial Year 2026	CI
03-27	Newbury Pharmaceuticals Seeks Shareholder Approval to Expand Loan Facility to SEK30 Million	MT

Newbury Pharmaceuticals AB Stock

Stocks

NEWBRY

SE0015244884

Drug Retailers

Valuation: Newbury Pharmaceuticals AB

Chart: Newbury Pharmaceuticals AB

Latest news: Newbury Pharmaceuticals AB

Analysts' recommendations: Newbury Pharmaceuticals AB

Press Releases: Newbury Pharmaceuticals AB

Quotes and Performance

Price Extremes

Managers and Directors: Newbury Pharmaceuticals AB

Retail - Drugs without Grocery

Financials

Company Profile

Quotes

Net sales - Rate of surprise

23-01-12	Redeye adjusts downwards its motivated value for Newbury Pharmaceuticals	FW
23-01-12	Redeye lowers motivated value for Newbury Pharmaceuticals to SEK 8.5 (9)	FW

10-26	Newbury Pharmaceuticals : international receives import approvals for 19 hospital product	PU
09-28	Newbury Pharmaceuticals secures exclusive rights to a 40-product hospital portfolio in Iraq	AQ
08-17	Newbury Pharmaceuticals : accelerates its neuroscience ambitions with a new partnership for Guanfacine tablets	PU
07-13	Newbury Pharmaceuticals Secures Generic Approval for Tofacitinib Newbury	AQ
07-10	Newbury Pharmaceuticals Secures Generic Approval for Dalbavancin Newbury	AQ

1 day	+1.28%
1 week	-8.14%
Current month	-31.60%
1 month	-31.00%
3 months	-42.55%
6 months	+19.25%
Current year	+37.39%

1 week	1.21	2
1 month	1.21	2.31
Current year	0.76	7.88
1 year	0.76	7.88
3 years	0.76	7.88
5 years	0.76	13.7
10 years	0.76	13.7

Manager	Title	Age	Since
Karl Karlsson CEO	Chief Executive Officer	52	2025-11-10
Christoffer Tell DFI	Director of Finance/CFO	39	2020-12-31
Andrea Karnitschky PRN	Corporate Officer/Principal	-	2022-07-31

Director	Title	Age	Since
Hakan Andreas Hedskog BRD	Director/Board Member	52	2019-12-31
Anil Okay BRD	Director/Board Member	40	2020-12-31
Johan Strömqvist BRD	Director/Board Member	50	2019-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEWBURY PHARMACEUTICALS AB	+1.28%	-8.14%	-25.12%	-44.17%	4.78M
JD HEALTH INTERNATIONAL INC.	-1.26%	-7.55%	-42.15%	+0.64%	14.81B
MATSUKIYOCOCOKARA & CO.	+3.05%	-0.91%	-6.76%	+1.21%	6.26B
TSURUHA HOLDINGS INC.	+2.77%	+0.79%	-15.86%	+5.06%	6.16B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-1.25%	-6.13%	-53.78%	-40.62%	5.75B
RAIA DROGASIL S.A.	-15.53%	-23.72%	-19.75%	-38.34%	5.11B
YIFENG PHARMACY CHAIN CO., LTD.	+1.16%	-1.75%	-1.14%	-9.60%	4.53B
COSMOS PHARMACEUTICAL CORPORATION	+1.67%	-4.41%	-11.84%	-19.55%	3.02B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-0.16%	+0.66%	+1.38%	-22.99%	3.15B
CLICKS GROUP LIMITED	-4.44%	-10.93%	-42.24%	-18.73%	2.99B
Average	-1.29%	-6.12%	-21.72%	-18.71%	5.18B
Weighted average by Cap.	-1.41%	-6.06%	-25.83%	-11.82%

	2024	2025
Net sales	36.83M 3.74M 3.35M 3.09M 2.79M 5.22M 356M 5.31M 14.69M 186M 14.02M 13.72M 590M	31.57M 3.2M 2.87M 2.65M 2.39M 4.48M 305M 4.55M 12.6M 160M 12.02M 11.76M 506M
Net income	-15.4M -1.56M -1.4M -1.29M -1.17M -2.18M -149M -2.22M -6.15M -77.88M -5.86M -5.74M -247M	-23.88M -2.42M -2.17M -2M -1.81M -3.39M -231M -3.44M -9.53M -121M -9.09M -8.9M -382M
Net Debt	-15.3M -1.55M -1.39M -1.28M -1.16M -2.17M -148M -2.21M -6.1M -77.36M -5.83M -5.7M -245M	-14.56M -1.48M -1.32M -1.22M -1.1M -2.07M -141M -2.1M -5.81M -73.61M -5.54M -5.43M -233M